Nilotinib in the Treatment of Systemic Sclerosis

The purpose of this study is to learn how safe and tolerable a medication called Nilotinib
(Tasigna) will be for patients diagnosed with Systemic Sclerosis. Systemic Sclerosis
(scleroderma) is an autoimmune disease that can involve the skin, the blood vessels, the
muscles and other connective tissues, and major organs including the lungs, kidneys,
gastrointestinal tract, and heart. The exact cause of this disorder is not known at this time
and no drug has been proven to cure scleroderma. Experiments done in animal models and
"test-tube" models of fibrosis suggest that Nilotinib may be a useful therapy for
scleroderma. Nilotinib is a medication on the market which has been FDA approved for the
treatment of a type of leukemia called chronic myelogenous leukemia (CML). It is an oral
medication, taken two times a day.

This is a 32 week, open-label, Phase IIa, single center clinical trial. The primary goal of
the study is to assess the safety and tolerability of Nilotinib in patients with scleroderma.
The secondary goal is to assess how effective Nilotinib is in treating patients with
scleroderma. The clinical tests performed such as the Modified Rodnan Skin Score, Pulmonary
Function Tests, Echocardiograms, Electrocardiograms, and the blood and skin collected in this
study will help determine whether this therapy is safe and effective, and also improve our
understanding of scleroderma.

Inclusion Criteria:

1. Age greater than or equal to eighteen years.

2. Clinical diagnosis of diffuse systemic sclerosis by ACR criteria, with a stable
modified Rodnan skin score in the one month preceding introduction of oral nilotinib
therapy. The modified Rodnan skin score must be greater than or equal to sixteen at
screening and initiation of therapy.

3. Disease duration of less than or equal to 3 years as defined by the date of onset of
the first non-Raynaud's symptom.

4. Estimated ejection fraction of greater than 50% by echocardiography

Exclusion Criteria:

1. Inability to render informed consent in accordance with institutional guidelines.

2. Disease duration of greater than 3 years.

3. Patients with mixed connective tissue disease or "overlap" (i.e. those who satisfy
more than one set of ACR criteria for a rheumatic disease.)

4. Limited scleroderma.

5. Systemic sclerosis-like illness associated with environmental or ingested agents such
as toxic rapeseed oil, vinyl chloride, or bleomycin.

6. Ongoing treatment with immunosuppressive therapies including cyclophosphamide,
azathioprine, mycophenolic acid, methotrexate, or cyclosporine, or use of those
medications within 1 month of trial entry.

7. The use of other anti-fibrotic agents including colchicine, D-penicillamine,
minocycline, or Type 1 oral Collagen in the month prior to enrollment.

8. Use in the prior month of corticosteroids at doses exceeding the equivalent of
prednisone 10 mg daily. Use of corticosteroid at < 10 mg of prednisone can continue
during the course of the study.

9. Concurrent serious medical condition which in the opinion of the investigator makes
the patient inappropriate for this study such as uncontrollable CHF, arrhythmia,
severe pulmonary or systemic hypertension, severe GI involvement, hepatic impairment,
serum creatinine of greater than 2.0, active infection, severe diabetes, unstable
atherosclerotic cardiovascular disease, malignancy, HIV, or severe peripheral vascular
disease.

10. History of pancreatitis.

11. Prolonged QTc interval defined as a QTc > 450 msec

12. Patients requiring the ongoing use of medications that are antiarrhythmics (including,
but not limited to amiodarone, disopyramide, procainamide, quinidine and sotalol) or
that prolong the QTc interval (including, but not limited to chloroquine,
halofantrine, clarithromycin, haloperidol, methadone, moxifloxacin, bepridil and
pimozide) will be excluded.

13. Patients requiring the ongoing use of medications that are potent inhibitors or
inducers of CYP3A4.

14. A positive pregnancy test at entry into this study. Men and women with reproductive
potential will be required to use effective means of contraception through the course
of the study.

15. Participation in another clinical research study involving the evaluation of another
investigational drug within ninety days of entry into this study.

16. The presence of severe lung disease as defined by a diffusion capacity of less than
30% of predicted.